Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1751 to 1760 of 2603 total matches.

Breathe Right Nasal Strips to Decrease Snoring

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 1994  (Issue 934)
nasal dilators (CNS, Chanhassen, MN) are adhesive strips 2 or 2 ⁄ 1 2 inches long with a plastic ...
Breathe Right, an adhesive bandage device that pulls open the nostrils, has been approved by the US Food and Drug Administration and is being heavily promoted to the general public as a treatment for snoring and night-time nasal congestion. The manufacturer's suggested retail price is $4.99 for a box of 10 strips.
Med Lett Drugs Ther. 1994 Oct 28;36(934):100 |  Show IntroductionHide Introduction

Peginterferon Alfa-2b (Sylatron) for Melanoma

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2011  (Issue 1373)
different between the two groups.1 ADVERSE EFFECTS — During the clinical trial, the most common adverse ...
The FDA has approved peginterferon alfa-2b (Sylatron – Merck) for adjuvant treatment of node-positive melanoma after surgical resection. Pegylated interferon has a longer duration of action than interferon alfa-2b (Intron A), which is also FDA-approved for adjuvant treatment of malignant melanoma after surgery, and can be given once a week, compared to 3-5 times a week for standard interferon.
Med Lett Drugs Ther. 2011 Sep 19;53(1373):76 |  Show IntroductionHide Introduction

Off-Label Use of Ketorolac for Athletic Injuries

   
The Medical Letter on Drugs and Therapeutics • May 14, 2012  (Issue 1390)
muscles, has become a common practice in US locker rooms.1 KETOROLAC — A non-selective NSAID available ...
Recent reports indicate that intramuscular (IM) injection of the nonsteroidal anti-inflammatory drug (NSAID) ketorolac (Toradol, and others), sometimes directly into injured muscles, has become a common practice in US locker rooms.
Med Lett Drugs Ther. 2012 May 14;54(1390):37 |  Show IntroductionHide Introduction

In Brief: Meningococcal Vaccine for Infants

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013  (Issue 1429)
, antibody levels against Hib were non-inferior to those with 2 standard monovalent Hib vaccines.1 ...
Rates of meningococcal disease are highest in infancy, but until recently no meningococcal vaccine was approved for use in this age group. MenHibrix (GSK), a new conjugate vaccine that protects against Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib), has been approved by the FDA for use in infants ≥6 weeks old and Menveo, a meningococcal vaccine already approved for patients ≥2 years old that protects against serogroups A, C, Y, and W-135, is now approved for use in infants ≥2 months old.SEROGROUPS — Five major serogroups of N. meningitidis, A, B, C,...
Med Lett Drugs Ther. 2013 Nov 11;55(1429):92 |  Show IntroductionHide Introduction

Sorafenib (Nexavar) for Thyroid Cancer

   
The Medical Letter on Drugs and Therapeutics • May 26, 2014  (Issue 1443)
cell and unresectable hepatocellular cancer.1 STANDARD TREATMENT — Surgery and radioactive iodine ...
The FDA has approved the use of the oral multikinase inhibitor sorafenib (Nexavar – Bayer) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer (papillary or follicular) refractory to radioactive iodine treatment. Sorafenib was approved earlier for treatment of advanced renal cell and unresectable hepatocellular cancer.
Med Lett Drugs Ther. 2014 May 26;56(1443):43-4 |  Show IntroductionHide Introduction

In Brief: New Indications for Secukinumab (Cosentyx)

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016  (Issue 1496)
and ankylosing spondylitis in adults.1 Secukinumab is one of the most effective drugs available for treatment ...
The FDA has approved the subcutaneous IL-17A antagonist secukinumab (Cosentyx - Novartis), which was first approved in 2015 for treatment of plaque psoriasis, for treatment of psoriatic arthritis and ankylosing spondylitis in adults.1 Secukinumab is one of the most effective drugs available for treatment of plaque psoriasis.2FDA approval of secukinumab for treatment of psoriatic arthritis was based on two randomized, double-blind trials with a primary endpoint of at least a 20% improvement in the American College of Rheumatology response criteria (ACR20) at 24 weeks. In both trials, ACR20...
Med Lett Drugs Ther. 2016 Jun 6;58(1496):76 |  Show IntroductionHide Introduction

In Brief: Erenumab (Aimovig) Hypersensitivity

   
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019  (Issue 1568)
of erenumabaooe (Aimovig)1, a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP ...
The FDA has approved changes to the labeling of erenumab-aooe (Aimovig)1, a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) blocker approved in 2018 for prevention of migraine. The new label contains a warning about hypersensitivity reactions, including rash, angioedema, and anaphylaxis, that have been reported with post-marketing use of the drug.According to the label, most of these reactions were not serious and occurred within hours after receiving the drug, but some occurred more than one week after administration. Because these reactions are voluntarily...
Med Lett Drugs Ther. 2019 Mar 25;61(1568):48 |  Show IntroductionHide Introduction

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
tonic-clonic” (see Table 1). The new terminology is used here. Controlled monotherapy trials ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction

Drugs for Assisted Reproduction

   
Treatment Guidelines from The Medical Letter • Oct 01, 2003  (Issue 14)
. (ISSN 1541-2784) Vol. 1 (Issue 14) October 2003 Published by The Medical Letter, Inc. 1000 Main ...
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
Treat Guidel Med Lett. 2003 Oct;1(14):89-92 |  Show IntroductionHide Introduction

In Brief: A Naloxone Auto-Injector (Evzio)

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014  (Issue 1444)
from opioid overdose in the US.1 Now the FDA has approved a more practical alternative for emergency ...
A recent Medical Letter article reported renewed interest in the intranasal administration (off-label) of the opioid antagonist naloxone because of an increase in deaths from opioid overdose in the US.1 Now the FDA has approved a more practical alternative for emergency treatment of life-threatening opioid overdose in adults and children: a single-dose naloxone auto-injector (Evzio – Kaleo) for intramuscular or subcutaneous use.Evzio will be available in kits containing two prefilled 0.4-mg auto-injectors with voice guidance and a "trainer" device that also has voice guidance, but does not...
Med Lett Drugs Ther. 2014 Jun 9;56(1444):45 |  Show IntroductionHide Introduction